Language
English
Publication Date
12-5-2022
Journal
Journal of the Pediatric Infectious Diseases Society
DOI
10.1093/jpids/piac087
PMID
36043874
PMCID
PMC9720369
PubMedCentral® Posted Date
8-31-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Leishmaniasis is a vector-borne disease caused by over 20 species of obligate intracellular protozoa belonging to the genus Leishmania. Leishmaniasis has a global distribution, including in the United States, and can cause a spectrum of clinical syndromes, including cutaneous, mucosal, and visceral diseases depending on host factors and the infecting Leishmania spp. Accurate diagnosis, including Leishmania species identification, is an important step to guide the most appropriate therapeutic intervention. Antileishmanial therapy is dependent on the Leishmania spp. identified, the clinical syndrome, and the child's immune system. However, many treatment regimens for children have been extrapolated from adult clinical trials, which may lead to underdosing and subsequent poor outcomes in infected children. Additional research is urgently needed to help guide therapy for children and determine appropriate antileishmanial agents, doses, and treatment courses for children with leishmaniasis.
Keywords
Child, Humans, United States, Leishmaniasis, Leishmania, Antiprotozoal Agents, Skin, Leishmaniasis, Cutaneous, : leishmaniasis, neglected tropical disease, parasites, tropical medicine
Published Open-Access
yes
Recommended Citation
, "How I Approach Leishmaniasis: Diagnosis and Treatment in the United States" (2022). Faculty, Staff and Students Publications. 3307.
https://digitalcommons.library.tmc.edu/baylor_docs/3307